Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics

LGND POWR Grades

• LGND scores best on the Growth dimension, with a Growth rank ahead of 76.18% of US stocks.
• The strongest trend for LGND is in Value, which has been heading down over the past 48 weeks.
• LGND ranks lowest in Stability; there it ranks in the 16th percentile.

LGND Stock Summary

• Price to trailing twelve month operating cash flow for LGND is currently 53.67, higher than 91.38% of US stocks with positive operating cash flow.
• Over the past twelve months, LGND has reported earnings growth of 2,313%, putting it ahead of 98.94% of US stocks in our set.
• Revenue growth over the past 12 months for Ligand Pharmaceuticals Inc comes in at 99.11%, a number that bests 93.4% of the US stocks we're tracking.
• Stocks with similar financial metrics, market capitalization, and price volatility to Ligand Pharmaceuticals Inc are DCTH, CRNC, WATT, EH, and PI.
• Visit LGND's SEC page to see the company's official filings. To visit the company's web site, go to www.ligand.com.

LGND Valuation Summary

• LGND's EV/EBIT ratio is 46.3; this is 58.02% higher than that of the median Healthcare stock.
• Over the past 243 months, LGND's price/sales ratio has gone down 0.9.
• Over the past 243 months, LGND's price/sales ratio has gone down 0.9.

Below are key valuation metrics over time for LGND.

LGND Growth Metrics

• Its year over year price growth rate is now at 22.75%.
• Its 2 year price growth rate is now at -39.03%.
• The 2 year cash and equivalents growth rate now stands at 130.34%.

LGND's revenue has moved up $9,336,000 over the prior 33 months.

The table below shows LGND's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-06-30	251.663	44.413	47.891
2021-03-31	208.408	48.418	39.252
2020-12-31	186.419	54.586	-2.985
2020-09-30	143.432	46.71	-16.111
2020-06-30	126.392	27.768	-24.661
2020-03-31	109.959	-57.672	-61.166

LGND's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• LGND has a Quality Grade of C, ranking ahead of 61.05% of graded US stocks.
• LGND's asset turnover comes in at 0.195 -- ranking 203rd of 677 Pharmaceutical Products stocks.
• IRWD, MNKD, and BMRN are the stocks whose asset turnover ratios are most correlated with LGND.

The table below shows LGND's key quality metrics over time.